Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design.
Future Oncol
; 17(16): 1987-2003, 2021 06.
Article
de En
| MEDLINE
| ID: mdl-33682447
ABSTRACT
Belantamab mafodotin (belamaf) is a BCMA-targeted antibody-drug conjugate recently approved as monotherapy for adults with relapsed/refractory multiple myeloma who have received ≥4 prior therapies. Belamaf binds to BCMA and eliminates myeloma cells by multimodal mechanisms of action. The cytotoxic and potential immunomodulatory properties of belamaf have led to novel combination studies with other anticancer therapies. Here, we describe the rationale and design of DREAMM-5, an ongoing Phase I/II platform study evaluating the safety and efficacy of belamaf combined with novel agents, including GSK3174998 (OX40 agonist), feladilimab (an ICOS; GSK3359609), nirogacestat (a gamma-secretase inhibitor; PF-03084014) and dostarlimab (a PD-1 blocker) versus belamaf monotherapy for patients with relapsed/refractory multiple myeloma. Clinical trial registration NCT04126200 (ClinicalTrials.gov).
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Plan de recherche
/
Protocoles de polychimiothérapie antinéoplasique
/
Antigène de maturation des cellules B
/
Récepteur au OX40
/
Myélome multiple
/
Récidive tumorale locale
Type d'étude:
Clinical_trials
Limites:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Langue:
En
Journal:
Future Oncol
Année:
2021
Type de document:
Article
Pays d'affiliation:
États-Unis d'Amérique